| Title |
Second-line afatinib administration in an elderly patient with squamous cell carcinoma
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, March 2017
|
| DOI | 10.2147/tcrm.s130816 |
| Pubmed ID | |
| Authors |
Wolfgang Hohenforst-Schmidt, Paul Zarogoulidis, Michael Steinheimer, Naim Benhassen, Chrysanthi Sardeli, Nikos Stalikas, Melpomeni Toitou, Haidong Huang |
| Abstract |
The majority of cases of lung cancer are still diagnosed at a late stage. At this stage, palliative therapeutic options including nonspecific cytotoxic drugs, targeted therapy, or immunotherapy can be utilized. In 2016, immunotherapy was approved in Europe for squamous cell carcinoma and adenocarcinoma. Moreover, afatinib was also approved as second-line therapy for squamous cell carcinoma. This article presents a case of a 76-year-old male with squamous cell carcinoma who received nab-paclitaxel as first-line therapy, and his treatment was switched to the tyrosine kinase inhibitor afatinib (40 mg) after disease progression with left lung atelectasis. After receiving afatinib for only 28 days, the atelectasis resolved. No adverse effects were observed from the afatinib therapy. In this case, afatinib 40 mg proved to be an effective alternative treatment for an elderly patient. Treatment choice should be based on the performance status of the patient, cost-effectiveness, and drug treatment guidelines. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 29% |
| Lecturer | 1 | 7% |
| Other | 1 | 7% |
| Student > Bachelor | 1 | 7% |
| Professor > Associate Professor | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 6 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 21% |
| Nursing and Health Professions | 1 | 7% |
| Economics, Econometrics and Finance | 1 | 7% |
| Agricultural and Biological Sciences | 1 | 7% |
| Social Sciences | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 6 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 March 2017.
All research outputs
#22,764,772
of 25,382,440 outputs
Outputs from Therapeutics and Clinical Risk Management
#1,204
of 1,323 outputs
Outputs of similar age
#285,015
of 324,443 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#22
of 24 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,443 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.